Allarity Therapeutics Launches Phase 2 Trial for Stenoparib

Allarity Therapeutics ( (ALLR) ) has shared an update.

On June 2, 2025, Allarity Therapeutics announced the enrollment of the first patient in its new Phase 2 clinical trial of stenoparib, aimed at treating advanced, platinum-resistant ovarian cancer. This trial seeks to accelerate the clinical development of stenoparib and its DRP® companion diagnostic towards potential FDA approval, focusing on patients with limited treatment options. The trial will explore the efficacy, safety, and optimal dosing of stenoparib, while advancing understanding of its WNT signaling pathway modulation, with significant clinical data expected by late summer 2026.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is dedicated to the development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to create a companion diagnostic for selecting patients likely to benefit most from stenoparib. Headquartered in the U.S. with a research facility in Denmark, Allarity aims to address significant unmet medical needs in cancer treatment.

Average Trading Volume: 1,549,966

Technical Sentiment Signal: Sell

Current Market Cap: $13.49M

See more data about ALLR stock on TipRanks’ Stock Analysis page.